Evidence map›Paper›PMID 22093188›Full record

ArticleLancet (London, England)2012

Treatment of prostate cancer metastases: more than semantics.

Christopher J Logothetis

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01859221 (Phase II Stereotactic Body Radiotherapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01859221 nacompletednot on this mapstarted 2013, after this paper: background citation

Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer

TypeinterventionalSponsorUniversity of FloridaRan2013 to 2022Enrolled39ConditionsOligometastatic Prostate CancerArmsStereotactic radiation
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Targeting bone physiology for the treatment of metastatic prostate cancer.Clinical advances in hematology & oncology : H&O · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Christopher J LogothetisUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. clogothe@mdanderson.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

OrchiectomyAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBone NeoplasmsDenosumabHumansMaleProstatic NeoplasmsRANK LigandAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDenosumabRANK Ligand

Identifiers

PMID22093188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.